Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Blaschke is Professor of Medicine and Molecular Pharmacology (Emeritus) at Stanford University, Adjunct Professor of Bioengineering and Therapeutic Sciences at UCSF and Adjunct Professor of Medicine at Indiana University. He joined the faculty at Stanford University School of Medicine in 1974. From November 2012 through 2015 Dr. Blaschke was a Senior Program Officer/Senior Advisor at the Bill and Melinda Gates Foundation and was a consultant to the BMGF. Dr. Blaschke was a member of the AIDS Clinical Trials Group and served as chair of the Pharmacology Committee. His research has focused on sources of variability in drug response. Studies of variability have emphasized modeling PK/PD relationships. His recent clinical efforts are directed at improving patient adherence in TB and other chronic diseases. Dr. Blaschke has over 180 original publications in peer reviewed journals. He is an Associate Editor of the Annual Review of Pharmacology and Toxicology.
Global Health, Clinical Pharmacology
Bill and Melinda Gates Foundation
Low- and middle-income populations
Treatment of HIV/AIDS
Indiana University School of Medicine
My ongoing Stanford research activities involve studies on the clinical pharmacology of drugs used in HIV-infected patients.A focus of my laboratory's efforts in investigating drugs used in HIV-infected patients is to optimize the individual benefit/risk of pharmacotherapy of HIV or opportunistic infections by discovering and quantifying the pharmacokinetics and pharmacodynamics (PK/PD) of drugs used in such therapy; i.e., the distribution of individual-specific dose-concentration-effect relationships in the population. My laboratory has a special interest in understanding the relationships between antiviral drug exposure and virologic and toxicological responses. In the past this has lead to studies examining drug-taking behavior in these patients, since exposure is a function of both individual variability in pharmacokinetics and individual patterns of drug-taking behavior.At the present time, my interests in HIV are in the access and quality of antiretroviral drugs for patients from less developed countries. The use of substandard drugs carries a high risk of promoting drug resistant variants of HIV, which could have widespread consequences over the long term. Another interest is drug-drug interactions between antiretroviral drugs and drugs used to treat opportunistic infections, in particular drugs used to treat tuberculosis.